Skip to main content
Back
LVZPF logo

Livzon Pharmaceutical Group Inc.

Data quality: 100%
Overbought
LVZPF
OTC Healthcare Drug Manufacturers - Specialty & Generic
$5.22
$0.00 (0.00%)
Mkt Cap: 6.06B
Day Range
$4.35 $5.22
52-Week Range
$3.43 $5.22
Volume
1
50D / 200D Avg
$5.22 / $4.66
Prev Close
$5.22

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 2.9 0.4
P/B 0.4 2.9
ROE % 14.8 3.8
Net Margin % 17.5 3.9
Rev Growth 5Y % 2.9 10.0
D/E 0.3 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 $2.66
$2.49 – $2.76
 13 B 1
FY2026 $2.44
$2.28 – $2.54
 12 B 1

Key Takeaways

Revenue grew 2.94% annually over 5 years — modest growth
ROE of 14.77% — decent returns on equity
Net margin of 17.45% shows strong profitability
Debt/Equity of 0.28 — conservative balance sheet
Generating 2.41B in free cash flow
P/E of 2.94 — trading at a low valuation

Growth

Revenue Growth (5Y)
2.94%
Revenue (1Y)-4.97%
Earnings (1Y)5.50%
FCF Growth (3Y)14.65%

Quality

Return on Equity
14.77%
ROIC11.99%
Net Margin17.45%
Op. Margin24.08%

Safety

Debt / Equity
0.28
Current Ratio2.15
Interest Coverage32.10

Valuation

P/E Ratio
2.94
P/B Ratio0.44
EV/EBITDA-0.29
Dividend Yield0.06%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -4.97% Revenue Growth (3Y) -3.29%
Earnings Growth (1Y) 5.50% Earnings Growth (3Y) 3.90%
Revenue Growth (5Y) 2.94% Earnings Growth (5Y) 4.70%
Profitability
Revenue (TTM) 11.81B Net Income (TTM) 2.06B
ROE 14.77% ROA 8.43%
Gross Margin 65.45% Operating Margin 24.08%
Net Margin 17.45% Free Cash Flow (TTM) 2.41B
ROIC 11.99% FCF Growth (3Y) 14.65%
Safety
Debt / Equity 0.28 Current Ratio 2.15
Interest Coverage 32.10 Dividend Yield 0.06%
Valuation
P/E Ratio 2.94 P/B Ratio 0.44
P/S Ratio 0.51 PEG Ratio 1.68
EV/EBITDA -0.29 Dividend Yield 0.06%
Market Cap 6.06B Enterprise Value -830.33M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 11.81B 12.43B 12.63B 12.06B 10.52B
Net Income 2.06B 1.95B 1.91B 1.78B 1.71B
EPS (Diluted) 2.24 2.10 2.04 1.90 1.83
Gross Profit 7.73B 7.66B 8.17B 7.81B 6.85B
Operating Income 2.84B 2.42B 2.35B 2.27B 2.50B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 24.46B 25.04B 24.86B 22.37B 20.59B
Total Liabilities 9.55B 10.28B 9.93B 8.06B 6.95B
Shareholders' Equity 13.86B 14.04B 13.88B 13.00B 12.11B
Total Debt 3.93B 3.48B 3.62B 2.69B 1.93B
Cash & Equivalents 10.83B 11.33B 10.41B 9.15B 9.95B
Current Assets 16.42B 17.27B 16.99B 14.67B 14.63B
Current Liabilities 7.63B 8.09B 7.40B 6.93B 6.08B

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#26 of 820
75
Value Defensive Investing (Benjamin Graham)
#9 of 708
78

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026